2023-03-30 17:59:02 ET
- Y-mAbs Therapeutics ( NASDAQ: YMAB ) has filed for a $150M mixed shelf offering.
- The filing does not necessarily indicate that a sale has begun or will occur in the future.
- The offering may include common stock, preferred stock, warrants, debt securities, warrants, and units.
- The company said it will use the proceeds for working capital, capital expenditures, operating expenditures, and general corporate purposes.
- Y-mAbs ( YMAB ) Thursday also reported its Q4 2022 results on Thursday, beating on the top and bottom lines .
- Read why Seeking Alpha contributor Avisol Capital Partners rates Y-mAbs ( YMAB ) a hold.
For further details see:
Y-mAbs Therapeutics files for $150M mixed shelf offering